So far the transrectal ultrasound guided (TRUS) biopsy has been the ‘gold standard’ for diagnosing prostate cancer. However, it is invasive and can lead to complications, so there is a need for new non-invasive diagnostic tools to avoid unnecessary biopsy...
The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...
Shockwave lithotripsy (SWL) treatment is a common, non-invasive urology procedure used for kidney stones nearly every day throughout the UK. In this study the team evaluated factors affecting treatment success of SWL treatment. The prospective data were collected from 2013...
SNNLive spoke with Andrew Tasker, CEO of Femeda Ltd. at the Planet MicroCap Showcase 2019 in Las Vegas, NV, and they discuss the following topics: Overview and history of Femeda, Update since our last interview...
Since its beginnings as an Interstitial Support Group back in 1994 Bladder Health UK has developed and grown into a well-respected provider of support, expertise and education to both patients and healthcare professionals. The charity's ambition is to continue to...
Present your innovative research on the world stage! 🌟
Submit your abstract for SIU 2025 Edinburgh by April 3 2025, and be part of shaping the future of urology.
Click the image to access
You can now access the SIU 2024 B2B GU Cancers Triad proceedings, published as a supplement to the February issue of SIUJ. Review the latest updates on bladder, kidney and prostate cancers that were presented by expert faculty. Access the...
Leann McLaughlin, a Uro-Oncology CNS who specialises in prostate cancer at Inverclyde Royal Hospital, NHS Greater Glasgow and Clyde, has won Urology and Continence Nurse of the Year at the British Journal of Nursing (BJN) Awards 2025. The prestigious event...
I was fortunate enough to be able to take some time out of my training after ST5 to pursue an Out Of Programme Experience (OOPE) year. During the Urolink meeting at the British Association of Urological Surgeons (BAUS) 2017 conference...
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...